A Phase 3 interventional study of V116 and PCV15 in Pneumonia, Pneumococcal, sponsored by Merck Sharp & Dohme LLC. Completed at 51 sites in 9 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pneumonia, Pneumococcal with a site in United States — none open to participants now, none under way, none of them phase 3. Pneumonia, Pneumococcal · United States.
Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 9th registered.
44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.
Browse Pneumonia, Pneumococcal studies →None of the 12 studies in Pneumonia, Pneumococcal with a site in United States is open now. The open studies under Pneumonia, Pneumococcal, anywhere →
Of the 1 Pneumonia, Pneumococcal study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 1
First in 2001; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 717 is above the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.
Median enrollment 431 across the 11 interventional studies, 782 across the 1 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 8 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 4 studies filed under Pneumonia, Pneumococcal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This a study of V116 in adults ≥50 years of age who previously received a pneumococcal vaccination ≥1 year before enrollment. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116.
Participants will be randomized to 1 of 3 cohorts depending upon prior vaccinations. Prior vaccinations by cohort include: PPSV23 (pneumococcal vaccine, polyvalent [23-valent], PNEUMOVAX™23) for Cohort 1; PCV13 (pneumococcal 13-valent conjugate vaccine; PREVNAR 13™) for Cohort 2; PCV15 (pneumococcal 15-valent conjugate vaccine; VAXNEUVANCE™), PCV20 (pneumococcal 20-valent conjugate vaccine; PREVNAR 20™), PCV13+PPSV23, PCV15+PPSV23, or PPSV23+PCV13 for Cohort 3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 on Day 1. Participants in this arm received PPSV23 prior to the enrollment.
Biological: V116
Participants will receive a single 0.5 mL IM injection of PCV15 on Day 1. Participants in this arm received PPSV23 prior to the enrollment.
Biological: PCV15
Participants will receive a single 0.5 mL IM injection of V116 on Day 1. Participants in this arm received PCV13 prior to the enrollment.
Biological: V116
Participants will receive a single 0.5 mL IM injection of PPSV23 on Day 1. Participants in this arm received PCV13 prior to the enrollment.
Biological: PPSV23
Participants will receive a single 0.5 mL IM injection of V116 on Day 1. Participants in this arm received PCV15, PCV20, PCV13+PPSV23, PCV15+PPSV23, or PPSV23+PCV13 prior to the enrollment.
Biological: V116
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Also known as: Pneumococcal 21-valent Conjugate Vaccine
Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension
Also known as: VAXNEUVANCE™
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Also known as: PNEUMOVAX™23
Percentage of Participants With Solicited Injection-site Adverse Events (AEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following any injection with either V116, PCV15, or PPSV23 the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were erythema, pain, and swelling.
Time frame: Up to 5 days post-vaccination
Percentage of Participants With Solicited Systemic AEs
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following any of the injections with either V116, PCV15, or PPSV23, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia.
Time frame: Up to 5 days post-vaccination
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)
A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. The percentage of participants with one or more SAE that were assessed by the investigator to be at least possibly related to the study vaccination are presented.
Time frame: Up to ~180 days
Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA)
OPA for the serotypes contained in V116 were determined using a multiplex opsonophagocytic assay (MOPA). GMT is defined as geometric mean titer (1/dil). Serotype-specific OPA GMTs with 95% confidence intervals are presented.
Time frame: 30 Days post-vaccination
Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG)
The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in V116 was determined using a pneumococcal electrochemiluminescence (PnECL) assay. Serotype-specific pneumococcal IgG GMCs with 95% confidence intervals are presented.
Time frame: 30 Days post-vaccination
Geometric Mean Fold Rise in Serotype-specific Opsonophagocytic Activity (OPA)
Activity for the serotypes contained in V116 was determined using a multiplex opsonophagocytic assay (MOPA). Geometric mean fold rise (GMFR) is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline. The GMFRs in OPA responses from baseline to 30 days post-vaccination with 95% confidence intervals are presented.
Time frame: Day 1 (Baseline) and 30 days post-vaccination
Percentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific OPA Responses
Activity for the serotypes contained in V116 was determined using a MOPA. The percentage of participants with a ≥4-fold rise from baseline to at 30 days post-vaccination for OPA responses with 95% confidence intervals are presented.
Time frame: Day 1 (Baseline) and 30 days post-vaccination
Geometric Mean Fold Rise of Serotype-specific IgG
Activity for the serotypes contained in V116 was determined using a PnECL assay. Geometric mean fold rise (GMFR) is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline. The GMFRs IgG responses from baseline to 30 days post-vaccination with 95% confidence intervals are presented.
Time frame: Day 1 (Baseline) and 30 days post-vaccination
Percentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific IgG Response
Activity for the serotypes contained in V116 was determined using a PnECL assay. The percentage of participants with a ≥4-fold rise from baseline to at 30 days post-vaccination for IgG responses with 95% confidence intervals are presented.
Time frame: Day 1 (Baseline) and 30 days post-vaccination
| Milestone | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| Started | 231 | 119 | 176 | 85 | 106 |
| Day 1 - vaccinated with v116 | 229 | 1 | 174 | 0 | 105 |
| Day 1 - vaccinated with pcv15 | 0 | 117 | 0 | 0 | 0 |
| Day 1 - vaccinated with ppsv23 | 0 | 1 | 0 | 85 | 0 |
| Completed | 229 | 118 | 173 | 85 | 105 |
| Not completed | 2 | 1 | 3 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Randomized by mistake without study treatment | 0 | 0 | 1 | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following any injection with either V116, PCV15, or PPSV23 the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were erythema, pain, and swelling.
| Percentage of Participants | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| Injection site erythema | 7.4 | 7.7 | 7.5 | 9.4 | 7.6 |
| Injection site pain | 35.7 | 43.6 | 41.4 | 47.1 | 43.8 |
| Injection site swelling | 8.3 | 8.5 | 4.6 | 16.5 | 10.5 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following any of the injections with either V116, PCV15, or PPSV23, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia.
| Percentage of Participants | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| Fatigue | 14.3 | 17.1 | 19.0 | 12.9 | 21.9 |
| Headache | 7.0 | 9.4 | 10.3 | 11.8 | 8.6 |
| Myalgia | 7.4 | 2.6 | 9.8 | 9.4 | 8.6 |
| Pyrexia | 1.7 | 2.6 | 2.9 | 1.2 | 0.0 |
A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. The percentage of participants with one or more SAE that were assessed by the investigator to be at least possibly related to the study vaccination are presented.
| Percentage of Participants | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 |
OPA for the serotypes contained in V116 were determined using a multiplex opsonophagocytic assay (MOPA). GMT is defined as geometric mean titer (1/dil). Serotype-specific OPA GMTs with 95% confidence intervals are presented.
| Titers | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| Serotype 3 | 262.1 (224.0 to 306.8) | 226.3 (182.0 to 281.4) | 391.1 (332.8 to 459.6) | 583.1 (453.5 to 749.6) | 318.3 (250.0 to 405.3) |
| Serotype 6A | 1653.5 (1347.2 to 2029.4) | 2076.1 (1571.4 to 2742.8) | 3624.0 (3099.2 to 4237.7) | 1812.3 (1226.6 to 2677.6) | 2097.3 (1693.4 to 2597.6) |
| Serotype 7F | 2184.4 (1891.4 to 2522.8) | 1750.3 (1404.7 to 2181.0) | 3129.8 (2609.9 to 3753.3) | 4057.0 (3211.2 to 5125.6) | 2051.3 (1630.2 to 2581.0) |
| Serotype 19A | 1513.8 (1318.4 to 1738.1) | 2022.9 (1634.1 to 2504.3) | 2528.9 (2201.7 to 2904.9) | 3241.5 (2646.0 to 3971.0) | 1533.8 (1272.4 to 1848.9) |
| Serotype 22F | 1983.8 (1698.3 to 2317.4) | 1595.6 (1227.1 to 2074.6) | 4389.2 (3541.1 to 5440.3) | 2524.0 (1834.5 to 3472.5) | 1913.5 (1453.5 to 2519.0) |
| Serotype 33F | 4311.9 (3625.1 to 5128.9) | 3397.2 (2665.3 to 4330.0) | 8162.9 (6407.2 to 10399.7) | 8761.9 (6157.4 to 12468.1) | 4654.3 (3532.1 to 6133.1) |
| Serotype 8 | 1273.0 (1115.1 to 1453.3) | 345.8 (250.5 to 477.5) | 2320.1 (1987.3 to 2708.7) | 2723.2 (2197.4 to 3374.8) | 1486.8 (1230.5 to 1796.6) |
| Serotype 9N | 3805.1 (3324.0 to 4356.0) | 2176.5 (1809.6 to 2617.9) | 7214.4 (6062.9 to 8584.6) | 6482.5 (4908.9 to 8560.7) | 4054.5 (3389.4 to 4850.2) |
| Serotype 10A | 1986.2 (1637.7 to 2408.9) | 467.5 (337.0 to 648.5) | 3976.8 (3360.7 to 4705.8) | 1797.6 (1136.2 to 2843.9) | 2564.0 (1959.1 to 3355.6) |
| Serotype 11A | 1998.5 (1696.9 to 2353.8) | 335.6 (228.9 to 491.8) | 2846.6 (2411.0 to 3360.8) | 1736.6 (1367.1 to 2206.1) | 2373.0 (1905.4 to 2955.4) |
| Serotype 12F | 981.8 (782.4 to 1232.1) | 80.5 (54.0 to 120.1) | 2252.6 (2120.5 to 3072.9) | 1402.5 (912.2 to 2156.4) | 1235.3 (948.3 to 1609.2) |
| Serotype 15A | 4184.9 (3548.3 to 4935.6) | 877.2 (616.2 to 1248.7) | 6185.2 (5179.3 to 7386.6) | 1668.2 (1234.4 to 2254.5) | 4328.6 (3378.7 to 5545.7) |
| Serotype 15C | 2307.8 (1878.4 to 2835.4) | 539.6 (371.1 to 784.6) | 4334.4 (3563.8 to 5271.5) | 1470.4 (978.6 to 2209.3) | 2191.9 (1573.2 to 3053.9) |
| Serotype 16F | 3060.5 (2633.8 to 3556.3) | 392.3 (301.3 to 510.8) | 4626.5 (3861.8 to 5542.6) | 832.8 (604.3 to 1147.6) | 2477.0 (1887.2 to 3251.2) |
| Serotype 17F | 3599.8 (3134.5 to 4134.3) | 939.6 (693.7 to 1272.6) | 5963.8 (5036.6 to 7061.7) | 4367.3 (3372.5 to 5655.7) | 3836.7 (3063.4 to 4805.1) |
| Serotype 20A | 2847.4 (2433.3 to 3331.8) | 1058.9 (829.9 to 1351.1) | 6005.5 (4919.8 to 7330.8) | 3393.9 (2536.9 to 4540.5) | 2433.4 (1880.5 to 3148.9) |
| Serotype 23A | 2363.9 (1857.4 to 3008.5) | 310.2 (202.1 to 476.0) | 4253.4 (3417.6 to 5293.5) | 433.6 (247.5 to 759.5) | 3967.2 (2764.8 to 5692.7) |
| Serotype 23B | 673.2 (517.1 to 876.4) | 153.0 (98.7 to 237.1) | 1530.7 (1196.5 to 1958.3) | 203.9 (127.6 to 325.6) | 844.0 (608.2 to 1171.4) |
| Serotype 24F | 1822.6 (1411.6 to 2353.3) | 106.6 (69.7 to 162.9) | 2746.1 (2257.9 to 3339.9) | 48.5 (28.6 to 82.1) | 2041.5 (1500.8 to 2777.1) |
| Serotype 31 | 3018.4 (2473.6 to 3683.3) | 113.2 (74.5 to 172.1) | 4413.5 (3530.2 to 5517.7) | 171.8 (99.9 to 295.6) | 3285.5 (2485.0 to 4343.8) |
| Serotype 35B | 6703.1 (5732.7 to 7837.8) | 1019.1 (739.9 to 1403.7) | 8143.5 (6761.4 to 9808.1) | 1527.7 (1169.5 to 1995.5) | 5836.8 (4693.6 to 7258.6) |
The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in V116 was determined using a pneumococcal electrochemiluminescence (PnECL) assay. Serotype-specific pneumococcal IgG GMCs with 95% confidence intervals are presented.
| μg/mL | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| Serotype 3 | 0.87 (0.77 to 0.99) | 0.80 (0.65 to 0.97) | 0.89 (0.77 to 1.03) | 1.58 (1.25 to 2.00) | 0.85 (0.70 to 1.03) |
| Serotype 6A | 4.69 (3.72 to 5.90) | 7.69 (5.60 to 10.57) | 7.81 (6.30 to 9.68) | 5.24 (3.62 to 7.56) | 5.48 (4.27 to 7.03) |
| Serotype 7F | 5.71 (4.89 to 6.68) | 6.45 (5.08 to 8.19) | 5.65 (4.75 to 6.73) | 8.34 (6.57 to 10.59) | 5.07 (4.12 to 6.23) |
| Serotype 19A | 8.54 (7.33 to 9.95) | 11.97 (9.40 to 15.24) | 9.12 (7.70 to 10.81) | 12.41 (9.57 to 16.11) | 8.06 (6.50 to 9.98) |
| Serotype 22F | 4.41 (3.69 to 5.28) | 4.33 (3.37 to 5.56) | 5.38 (4.34 to 6.66) | 2.87 (2.12 to 3.87) | 3.08 (2.36 to 4.01) |
| Serotype 33F | 13.36 (11.22 to 15.91) | 12.72 (10.37 to 15.61) | 15.04 (12.31 to 18.37) | 13.92 (10.23 to 18.94) | 9.66 (7.53 to 12.40) |
| Serotype 8 | 9.58 (8.21 to 11.17) | 3.56 (2.74 to 4.62) | 11.29 (9.28 to 13.73) | 14.47 (10.86 to 19.27) | 7.48 (5.87 to 9.53) |
| Serotype 9N | 7.06 (5.92 to 8.43) | 3.59 (2.83 to 4.55) | 8.48 (6.89 to 10.44) | 7.32 (5.47 to 9.78) | 4.15 (3.23 to 5.34) |
| Serotype 10A | 9.86 (7.99 to 12.18) | 2.77 (2.12 to 3.63) | 18.21 (14.30 to 23.18) | 7.29 (4.94 to 10.74) | 10.03 (7.21 to 13.98) |
| Serotype 11A | 7.16 (6.09 to 8.42) | 2.06 (1.65 to 2.58) | 9.13 (7.44 to 11.22) | 3.95 (2.98 to 5.23) | 4.78 (3.79 to 6.03) |
| Serotype 12F | 1.46 (1.18 to 1.81) | 0.41 (0.30 to 0.55) | 1.91 (1.44 to 2.53) | 1.01 (0.65 to 1.56) | 0.96 (0.70 to 1.31) |
| Serotype 15A | 16.35 (13.45 to 19.88) | 1.56 (1.19 to 2.05) | 20.24 (15.92 to 25.75) | 2.15 (1.52 to 3.03) | 11.16 (7.91 to 15.75) |
| Serotype 15C | 11.08 (9.01 to 13.62) | 3.25 (2.37 to 4.45) | 16.67 (12.78 to 21.76) | 4.31 (2.91 to 6.38) | 6.51 (4.72 to 8.99) |
| Serotype 16F | 4.69 (3.75 to 5.87) | 0.37 (0.28 to 0.48) | 4.04 (3.19 to 5.10) | 0.30 (0.22 to 0.41) | 2.46 (1.78 to 3.41) |
| Serotype 17F | 13.20 (11.18 to 15.58) | 2.68 (2.08 to 3.46) | 14.96 (12.37 to 18.08) | 7.23 (5.26 to 9.92) | 9.92 (7.86 to 12.53) |
| Serotype 20A | 14.83 (12.37 to 17.77) | 4.93 (3.83 to 6.36) | 22.21 (17.77 to 27.75) | 10.73 (7.48 to 15.41) | 12.16 (8.99 to 16.46) |
| Serotype 23A | 5.38 (4.19 to 6.90) | 0.75 (0.55 to 1.02) | 6.03 (4.55 to 7.99) | 0.62 (0.43 to 0.90) | 4.25 (2.88 to 6.26) |
| Serotype 23B | 6.66 (5.53 to 8.03) | 2.61 (1.96 to 3.48) | 6.00 (4.91 to 7.33) | 2.31 (1.75 to 3.06) | 5.05 (3.90 to 6.54) |
| Serotype 24F | 10.05 (7.59 to 13.32) | 0.49 (0.39 to 0.61) | 7.48 (5.45 to 10.46) | 0.31 (0.23 to 0.42) | 6.12 (3.84 to 9.75) |
| Serotype 31 | 4.48 (3.66 to 5.48) | 0.37 (0.30 to 0.47) | 3.58 (2.87 to 4.46) | 0.32 (0.24 to 0.44) | 3.66 (2.64 to 5.08) |
| Serotype 35B | 26.31 (21.60 to 32.04) | 1.45 (1.18 to 1.78) | 24.55 (20.09 to 30.01) | 1.45 (1.17 to 1.80) | 18.15 (13.61 to 24.21) |
Activity for the serotypes contained in V116 was determined using a multiplex opsonophagocytic assay (MOPA). Geometric mean fold rise (GMFR) is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline. The GMFRs in OPA responses from baseline to 30 days post-vaccination with 95% confidence intervals are presented.
| Ratio | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| Serotype 3 | 4.4 (3.7 to 5.3) | 4.0 (3.1 to 5.3) | 6.2 (5.0 to 7.6) | 7.5 (5.3 to 10.5) | 5.0 (3.6 to 7.0) |
| Serotype 6A | 6.2 (5.0 to 7.7) | 7.1 (4.9 to 10.3) | 4.2 (3.3 to 5.3) | 1.8 (1.4 to 2.4) | 5.5 (4.1 to 7.4) |
| Serotype 7F | 4.1 (3.3 to 5.1) | 3.9 (2.8 to 5.4) | 4.6 (3.6 to 5.9) | 4.2 (3.1 to 5.8) | 3.9 (2.9 to 5.3) |
| Serotype 19A | 2.4 (2.0 to 2.8) | 3.3 (2.5 to 4.4) | 2.8 (2.3 to 3.3) | 3.6 (2.7 to 4.7) | 2.5 (1.8 to 3.3) |
| Serotype 22F | 7.0 (5.5 to 9.0) | 7.1 (4.8 to 10.6) | 26.3 (17.7 to 39.2) | 14.8 (8.7 to 25.1) | 7.5 (4.9 to 11.4) |
| Serotype 33F | 2.2 (1.8 to 2.6) | 1.7 (1.3 to 2.4) | 6.3 (4.8 to 8.4) | 9.2 (5.6 to 15.3) | 2.7 (2.0 to 3.7) |
| Serotype 8 | 2.8 (2.4 to 3.4) | 0.9 (0.7 to 1.0) | 16.6 (12.2 to 22.7) | 18.6 (11.9 to 29.1) | 3.8 (2.7 to 5.3) |
| Serotype 9N | 2.3 (2.0 to 2.7) | 1.4 (1.1 to 1.7) | 5.9 (4.7 to 7.4) | 6.8 (4.7 to 9.8) | 3.5 (2.7 to 4.5) |
| Serotype 10A | 4.3 (3.5 to 5.4) | 1.0 (0.9 to 1.2) | 17.1 (12.7 to 23.0) | 11.8 (7.5 to 18.6) | 4.7 (3.4 to 6.5) |
| Serotype 11A | 6.5 (5.2 to 8.2) | 1.2 (0.9 to 1.7) | 21.0 (14.6 to 30.4) | 9.2 (5.9 to 14.4) | 9.5 (6.2 to 14.4) |
| Serotype 12F | 11.8 (9.0 to 15.4) | 1.1 (1.0 to 1.3) | 82.2 (62.9 to 107.4) | 41.9 (26.1 to 67.2) | 13.7 (9.0 to 20.8) |
| Serotype 15A | 5.6 (4.3 to 7.4) | 1.2 (0.9 to 1.5) | 9.0 (6.8 to 11.8) | 3.0 (2.0 to 4.5) | 7.2 (4.6 to 11.2) |
| Serotype 15C | 8.5 (6.7 to 10.9) | 1.3 (1.0 to 1.7) | 30.6 (22.5 to 41.5) | 12.7 (8.5 to 18.8) | 11.6 (8.1 to 16.4) |
| Serotype 16F | 7.1 (5.9 to 8.5) | 1.1 (0.9 to 1.3) | 9.8 (7.8 to 12.4) | 2.0 (1.5 to 2.7) | 7.2 (5.5 to 9.6) |
| Serotype 17F | 3.7 (3.0 to 4.5) | 0.9 (0.8 to 1.1) | 13.5 (9.5 to 19.2) | 8.1 (5.6 to 11.7) | 6.5 (4.6 to 9.3) |
| Serotype 20A | 3.7 (3.0 to 4.5) | 0.9 (0.8 to 1.0) | 12.2 (9.3 to 16.0) | 6.0 (4.4 to 8.3) | 4.4 (3.1 to 6.1) |
| Serotype 23A | 8.4 (6.2 to 11.6) | 1.4 (1.0 to 1.9) | 19.0 (13.5 to 26.9) | 2.5 (1.3 to 4.9) | 16.3 (10.3 to 25.7) |
| Serotype 23B | 21.4 (16.2 to 28.1) | 4.2 (2.9 to 6.0) | 35.5 (25.9 to 48.6) | 5.2 (3.5 to 7.6) | 26.1 (17.5 to 38.9) |
| Serotype 24F | 25.8 (19.5 to 34.0) | 1.0 (0.8 to 1.3) | 31.1 (22.8 to 42.6) | 0.9 (0.7 to 1.3) | 39.5 (27.4 to 56.9) |
| Serotype 31 | 16.7 (12.5 to 22.3) | 0.9 (0.7 to 1.2) | 35.6 (24.8 to 51.2) | 1.7 (1.1 to 2.6) | 30.5 (19.1 to 48.6) |
| Serotype 35B | 6.0 (4.8 to 7.4) | 1.0 (0.8 to 1.2) | 7.2 (5.6 to 9.2) | 1.4 (1.1 to 1.8) | 5.7 (4.2 to 7.9) |
Activity for the serotypes contained in V116 was determined using a MOPA. The percentage of participants with a ≥4-fold rise from baseline to at 30 days post-vaccination for OPA responses with 95% confidence intervals are presented.
| Percentage of Participants | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| Serotype 3 | 54.9 (46.9 to 62.6) | 54.9 (44.2 to 65.4) | 64.1 (55.3 to 72.3) | 66.2 (53.7 to 77.2) | 48.7 (37.0 to 60.4) |
| Serotype 6A | 57.9 (50.1 to 65.4) | 58.6 (47.6 to 69.1) | 46.3 (37.7 to 55.1) | 18.2 (9.8 to 29.6) | 56.2 (45.3 to 66.7) |
| Serotype 7F | 38.5 (31.7 to 45.6) | 43.1 (33.4 to 53.3) | 44.5 (36.3 to 53.0) | 49.3 (37.0 to 61.6) | 38.0 (28.1 to 48.8) |
| Serotype 19A | 28.4 (22.1 to 35.2) | 34.6 (25.6 to 44.6) | 33.6 (26.0 to 41.7) | 38.9 (27.6 to 51.1) | 30.0 (20.8 to 40.6) |
| Serotype 22F | 53.9 (46.6 to 61.1) | 54.9 (44.7 to 64.8) | 77.4 (69.0 to 84.4) | 65.6 (52.7 to 77.1) | 50.0 (39.5 to 60.5) |
| Serotype 33F | 19.8 (14.2 to 26.4) | 19.4 (11.9 to 28.9) | 52.0 (42.9 to 61.0) | 56.0 (41.3 to 70.0) | 29.4 (20.0 to 40.3) |
| Serotype 8 | 33.3 (26.8 to 40.4) | 2.8 (0.6 to 7.9) | 70.2 (62.2 to 77.4) | 74.6 (62.9 to 84.2) | 34.4 (25.0 to 44.8) |
| Serotype 9N | 22.0 (16.3 to 28.7) | 6.5 (2.6 to 12.9) | 57.4 (48.6 to 65.8) | 67.9 (53.7 to 80.1) | 39.1 (28.8 to 50.1) |
| Serotype 10A | 46.0 (38.9 to 53.2) | 2.7 (0.6 to 7.7) | 74.3 (66.5 to 81.1) | 67.6 (55.5 to 78.2) | 49.5 (38.9 to 60.0) |
| Serotype 11A | 53.8 (46.3 to 61.1) | 12.1 (6.2 to 20.6) | 73.3 (64.8 to 80.6) | 53.8 (41.0 to 66.3) | 59.0 (47.7 to 69.7) |
| Serotype 12F | 62.8 (55.8 to 69.4) | 6.3 (2.5 to 12.5) | 93.0 (87.8 to 96.5) | 81.9 (71.1 to 90.0) | 60.2 (49.5 to 70.2) |
| Serotype 15A | 53.5 (45.0 to 61.9) | 12.8 (6.3 to 22.3) | 70.9 (61.5 to 79.2) | 35.0 (20.6 to 51.7) | 59.7 (46.4 to 71.9) |
| Serotype 15C | 61.4 (54.2 to 68.3) | 10.2 (5.2 to 17.5) | 84.4 (77.3 to 90.0) | 72.1 (59.9 to 82.3) | 72.0 (60.9 to 81.3) |
| Serotype 16F | 68.0 (60.5 to 74.9) | 8.0 (3.5 to 15.2) | 70.5 (61.9 to 78.1) | 30.9 (20.2 to 43.3) | 70.9 (60.1 to 80.2) |
| Serotype 17F | 37.7 (30.7 to 45.2) | 2.0 (0.2 to 7.0) | 74.1 (65.2 to 81.8) | 62.5 (49.5 to 74.3) | 54.4 (42.8 to 65.7) |
| Serotype 20A | 37.5 (30.5 to 44.9) | 2.9 (0.6 to 8.1) | 76.7 (68.5 to 83.7) | 60.9 (48.4 to 72.4) | 46.9 (35.7 to 58.3) |
| Serotype 23A | 59.9 (51.8 to 67.6) | 21.1 (12.5 to 31.9) | 73.7 (64.8 to 81.4) | 34.2 (19.6 to 51.4) | 80.0 (68.2 to 88.9) |
| Serotype 23B | 74.9 (68.1 to 80.9) | 40.4 (31.1 to 50.2) | 80.6 (73.5 to 86.5) | 43.7 (31.9 to 56.0) | 80.9 (71.4 to 88.2) |
| Serotype 24F | 80.2 (73.8 to 85.7) | 7.7 (3.1 to 15.2) | 81.9 (74.1 to 88.2) | 4.9 (1.0 to 13.7) | 89.0 (80.2 to 94.9) |
| Serotype 31 | 70.9 (63.7 to 77.5) | 8.2 (3.6 to 15.6) | 81.3 (73.7 to 87.5) | 18.0 (9.4 to 30.0) | 82.1 (72.3 to 89.6) |
| Serotype 35B | 55.2 (47.7 to 62.5) | 7.5 (3.3 to 14.3) | 65.3 (56.9 to 73.0) | 7.0 (2.3 to 15.7) | 57.6 (46.4 to 68.3) |
Activity for the serotypes contained in V116 was determined using a PnECL assay. Geometric mean fold rise (GMFR) is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline. The GMFRs IgG responses from baseline to 30 days post-vaccination with 95% confidence intervals are presented.
| Ratio | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| Serotype 3 | 3.6 (3.2 to 4.0) | 3.1 (2.6 to 3.7) | 3.7 (3.2 to 4.3) | 5.7 (4.3 to 7.4) | 2.9 (2.3 to 3.5) |
| Serotype 6A | 5.9 (5.0 to 7.1) | 8.0 (6.1 to 10.6) | 3.3 (2.7 to 4.0) | 2.5 (1.9 to 3.2) | 4.4 (3.4 to 5.7) |
| Serotype 7F | 3.3 (2.8 to 3.8) | 2.9 (2.3 to 3.5) | 3.2 (2.7 to 3.8) | 3.2 (2.6 to 3.9) | 3.2 (2.6 to 4.0) |
| Serotype 19A | 2.3 (2.0 to 2.7) | 3.4 (2.8 to 4.2) | 2.2 (1.9 to 2.5) | 3.0 (2.4 to 3.6) | 2.0 (1.7 to 2.4) |
| Serotype 22F | 4.2 (3.6 to 4.9) | 3.4 (2.8 to 4.2) | 14.3 (11.4 to 18.0) | 8.5 (6.2 to 11.6) | 3.5 (2.7 to 4.6) |
| Serotype 33F | 2.2 (1.9 to 2.5) | 1.8 (1.5 to 2.1) | 8.6 (7.1 to 10.5) | 10.5 (7.9 to 13.9) | 2.4 (1.9 to 3.0) |
| Serotype 8 | 2.7 (2.4 to 3.1) | 1.0 (0.9 to 1.1) | 12.1 (9.8 to 15.0) | 14.4 (10.3 to 20.0) | 2.3 (1.9 to 2.8) |
| Serotype 9N | 2.9 (2.4 to 3.4) | 1.4 (1.2 to 1.6) | 8.7 (7.1 to 10.6) | 9.1 (6.8 to 12.1) | 3.2 (2.6 to 3.9) |
| Serotype 10A | 4.4 (3.7 to 5.2) | 1.0 (0.9 to 1.0) | 18.9 (15.3 to 23.4) | 10.1 (7.6 to 13.4) | 4.2 (3.1 to 5.5) |
| Serotype 11A | 4.1 (3.6 to 4.7) | 1.0 (0.9 to 1.0) | 10.3 (8.5 to 12.6) | 5.6 (4.4 to 7.2) | 3.5 (2.7 to 4.3) |
| Serotype 12F | 4.2 (3.6 to 5.0) | 1.0 (0.9 to 1.1) | 14.2 (11.3 to 17.9) | 8.4 (5.8 to 12.0) | 3.5 (2.7 to 4.5) |
| Serotype 15A | 12.2 (10.1 to 14.7) | 1.0 (0.9 to 1.1) | 24.5 (19.7 to 30.3) | 2.4 (2.0 to 3.0) | 16.6 (12.0 to 22.9) |
| Serotype 15C | 5.8 (4.9 to 6.9) | 1.0 (0.9 to 1.2) | 18.8 (14.9 to 23.8) | 6.2 (4.8 to 8.2) | 6.4 (5.0 to 8.1) |
| Serotype 16F | 15.2 (12.7 to 18.2) | 1.1 (1.0 to 1.2) | 15.7 (12.9 to 19.0) | 1.6 (1.3 to 1.8) | 11.9 (9.2 to 15.4) |
| Serotype 17F | 4.7 (4.0 to 5.5) | 1.0 (0.9 to 1.1) | 17.4 (14.3 to 21.1) | 10.5 (7.8 to 14.1) | 3.8 (2.9 to 5.0) |
| Serotype 20A | 3.8 (3.3 to 4.4) | 1.0 (0.9 to 1.1) | 14.8 (12.2 to 17.9) | 8.5 (6.4 to 11.4) | 3.7 (2.9 to 4.8) |
| Serotype 23A | 13.5 (11.1 to 16.5) | 1.8 (1.5 to 2.2) | 18.9 (15.3 to 23.4) | 2.3 (1.9 to 2.7) | 13.1 (9.6 to 17.7) |
| Serotype 23B | 8.2 (6.7 to 10.0) | 2.7 (2.1 to 3.5) | 7.3 (6.0 to 8.9) | 2.3 (1.9 to 2.9) | 7.3 (5.4 to 9.7) |
| Serotype 24F | 26.9 (21.8 to 33.1) | 1.0 (0.9 to 1.1) | 21.7 (17.3 to 27.2) | 1.0 (0.9 to 1.1) | 24.4 (17.1 to 34.9) |
| Serotype 31 | 13.1 (11.0 to 15.6) | 1.1 (1.0 to 1.2) | 14.4 (11.9 to 17.3) | 1.5 (1.3 to 1.8) | 13.0 (9.9 to 17.0) |
| Serotype 35B | 16.8 (13.9 to 20.3) | 1.0 (0.9 to 1.0) | 15.6 (12.9 to 18.7) | 0.9 (0.9 to 1.0) | 15.7 (11.9 to 20.8) |
Activity for the serotypes contained in V116 was determined using a PnECL assay. The percentage of participants with a ≥4-fold rise from baseline to at 30 days post-vaccination for IgG responses with 95% confidence intervals are presented.
| Percentage of Participants | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| Serotype 3 | 42.7 (36.1 to 49.6) | 36.8 (28.0 to 46.2) | 40.7 (33.2 to 48.6) | 54.3 (42.9 to 65.4) | 35.4 (26.0 to 45.6) |
| Serotype 6A | 56.2 (49.3 to 62.8) | 65.0 (55.6 to 73.5) | 35.9 (28.7 to 43.7) | 27.2 (17.9 to 38.2) | 45.5 (35.4 to 55.8) |
| Serotype 7F | 34.7 (28.4 to 41.4) | 29.9 (21.8 to 39.1) | 37.7 (30.4 to 45.5) | 33.3 (23.2 to 44.7) | 37.4 (27.9 to 47.7) |
| Serotype 19A | 24.7 (19.1 to 30.9) | 37.6 (28.8 to 47.0) | 19.8 (14.0 to 26.6) | 33.3 (23.2 to 44.7) | 19.2 (12.0 to 28.3) |
| Serotype 22F | 39.3 (32.8 to 46.1) | 35.0 (26.5 to 44.4) | 78.4 (71.4 to 84.4) | 65.4 (54.0 to 75.7) | 43.4 (33.5 to 53.8) |
| Serotype 33F | 19.1 (14.1 to 24.9) | 12.8 (7.4 to 20.3) | 72.5 (65.0 to 79.1) | 75.3 (64.5 to 84.2) | 27.3 (18.8 to 37.1) |
| Serotype 8 | 29.5 (23.6 to 36.0) | 0.9 (0.0 to 4.7) | 78.4 (71.4 to 84.4) | 76.5 (65.8 to 85.2) | 26.3 (17.9 to 36.1) |
| Serotype 9N | 31.8 (25.7 to 38.4) | 7.7 (3.6 to 14.1) | 68.9 (61.2 to 75.8) | 72.8 (61.8 to 82.1) | 36.4 (26.9 to 46.6) |
| Serotype 10A | 45.5 (38.7 to 52.3) | 0.9 (0.0 to 4.7) | 82.6 (76.0 to 88.1) | 80.2 (69.9 to 88.3) | 46.5 (36.4 to 56.8) |
| Serotype 11A | 43.8 (37.2 to 50.7) | 0.0 (0.0 to 3.1) | 72.5 (65.0 to 79.1) | 63.0 (51.5 to 73.4) | 43.4 (33.5 to 53.8) |
| Serotype 12F | 44.5 (37.9 to 51.4) | 2.6 (0.5 to 7.3) | 75.4 (68.2 to 81.8) | 60.5 (49.0 to 71.2) | 39.4 (29.7 to 49.7) |
| Serotype 15A | 73.6 (67.3 to 79.3) | 0.9 (0.0 to 4.7) | 89.8 (84.2 to 94.0) | 28.4 (18.9 to 39.5) | 77.8 (68.3 to 85.5) |
| Serotype 15C | 57.5 (50.7 to 64.2) | 3.4 (0.9 to 8.5) | 80.1 (73.2 to 85.9) | 64.2 (52.8 to 74.6) | 66.7 (56.5 to 75.8) |
| Serotype 16F | 82.1 (76.4 to 87.0) | 2.6 (0.5 to 7.3) | 84.9 (78.6 to 90.0) | 13.6 (7.0 to 23.0) | 77.8 (68.3 to 85.5) |
| Serotype 17F | 48.9 (42.1 to 55.7) | 1.7 (0.2 to 6.0) | 83.8 (77.4 to 89.1) | 74.1 (63.1 to 83.2) | 44.4 (34.5 to 54.8) |
| Serotype 20A | 36.5 (30.1 to 43.3) | 0.9 (0.0 to 4.7) | 83.2 (76.7 to 88.6) | 69.1 (57.9 to 78.9) | 49.5 (39.3 to 59.7) |
| Serotype 23A | 77.6 (71.5 to 83.0) | 17.1 (10.8 to 25.2) | 86.7 (80.6 to 91.5) | 21.0 (12.7 to 31.5) | 77.8 (68.3 to 85.5) |
| Serotype 23B | 64.8 (58.1 to 71.2) | 26.5 (18.8 to 35.5) | 60.5 (52.6 to 67.9) | 21.0 (12.7 to 31.5) | 64.6 (54.4 to 74.0) |
| Serotype 24F | 85.4 (80.0 to 89.8) | 0.0 (0.0 to 3.1) | 88.0 (82.1 to 92.5) | 0.0 (0.0 to 4.5) | 83.8 (75.1 to 90.5) |
| Serotype 31 | 79.7 (73.8 to 84.9) | 2.6 (0.5 to 7.3) | 84.4 (78.0 to 89.6) | 11.1 (5.2 to 20.0) | 80.8 (71.7 to 88.0) |
| Serotype 35B | 83.9 (78.4 to 88.6) | 0.0 (0.0 to 3.1) | 82.6 (76.0 to 88.1) | 0.0 (0.0 to 4.5) | 84.8 (76.2 to 91.3) |
Collected over Up to approximately 30 days post-vaccination for non-serious adverse events (AEs) and up to approximately 180 days for serious AEs and deaths.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: V116 | 0/231 (0%) | 2/230 (0.9%) | 107/230 (46.5%) |
| Cohort 1: PCV15 | 0/119 (0%) | 4/117 (3.4%) | 66/117 (56.4%) |
| Cohort 2: V116 | 0/176 (0%) | 2/174 (1.1%) | 85/174 (48.9%) |
| Cohort 2: PPSV23 | 0/85 (0%) | 3/85 (3.5%) | 52/85 (61.2%) |
| Cohort 3: V116 | 0/106 (0%) | 2/105 (1.9%) | 51/105 (48.6%) |
| Event | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| CholangitisHepatobiliary disorders | 0/230 | 0/117 | 0/174 | 1/85 | 0/105 |
| Ischaemic strokeNervous system disorders | 0/230 | 0/117 | 0/174 | 1/85 | 0/105 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/230 | 0/117 | 1/174 | 1/85 | 0/105 |
| CholelithiasisHepatobiliary disorders | 0/230 | 0/117 | 0/174 | 0/85 | 1/105 |
| Urinary tract infectionInfections and infestations | 0/230 | 0/117 | 0/174 | 0/85 | 1/105 |
| Cardiac failureCardiac disorders | 0/230 | 1/117 | 0/174 | 0/85 | 0/105 |
| Myocardial ischaemiaCardiac disorders | 0/230 | 1/117 | 0/174 | 0/85 | 0/105 |
| Aortoenteric fistulaGastrointestinal disorders | 0/230 | 1/117 | 0/174 | 0/85 | 0/105 |
| Mallory-Weiss syndromeGastrointestinal disorders | 0/230 | 1/117 | 0/174 | 0/85 | 0/105 |
| Small intestinal perforationGastrointestinal disorders | 0/230 | 1/117 | 0/174 | 0/85 | 0/105 |
| Event | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 |
|---|---|---|---|---|---|
| Injection site painGeneral disorders | 82/230 | 51/117 | 72/174 | 40/85 | 46/105 |
| FatigueGeneral disorders | 33/230 | 20/117 | 33/174 | 12/85 | 23/105 |
| Injection site swellingGeneral disorders | 20/230 | 10/117 | 8/174 | 14/85 | 11/105 |
| HeadacheNervous system disorders | 17/230 | 11/117 | 18/174 | 10/85 | 9/105 |
| MyalgiaMusculoskeletal and connective tissue disorders | 17/230 | 5/117 | 17/174 | 9/85 | 9/105 |
| Injection site erythemaGeneral disorders | 19/230 | 9/117 | 14/174 | 8/85 | 8/105 |
| Age, Continuous(Years) | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 | Total |
|---|---|---|---|---|---|---|
| Mean | 68.8 ± 7.5 | 69.0 ± 7.1 | 65.4 ± 7.8 | 65.4 ± 6.6 | 71.0 ± 7.6 | 67.9 ± 7.7 |
| Sex: Female, Male(Participants) | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 | Total |
|---|---|---|---|---|---|---|
| Female | 117 | 60 | 101 | 49 | 56 | 383 |
| Male | 114 | 59 | 75 | 36 | 50 | 334 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 22 | 17 | 34 | 16 | 14 | 103 |
| Not Hispanic or Latino | 207 | 102 | 142 | 69 | 92 | 612 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Cohort 1: V116 | Cohort 1: PCV15 | Cohort 2: V116 | Cohort 2: PPSV23 | Cohort 3: V116 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 96 | 47 | 55 | 25 | 13 | 236 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 3 | 3 | 1 | 6 | 19 |
| White | 127 | 69 | 118 | 59 | 86 | 459 |
| More than one race | 2 | 0 | 0 | 0 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jul 2022 to primary completion in May 2023, 10 months.
Results were first posted in May 2024, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine